In a nutshell This study is evaluating the effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for children with advanced Hodgkin lymphoma (HL). The main outcome to be measured will be the number of patients who respond to treatment. The details Brentuximab vedotin is being tested to treat children who have advanced HL. Brentuximab...
Read MorePerformance status -0 – Asymptomatic Posts on Medivizor
Looking for young patients with B-cell acute lymphoblastic leukemia to test a new T-cell therapy
In a nutshell This phase 2 trial is evaluating the effectiveness of huCART19 cell therapy in young patients with high-risk B-cell acute lymphoblastic leukemia (ALL). The main outcome to be measured will be survival without a treatment-related complication. This study is being conducted in Philadelphia, Pennsylvania, United States. The details Acute...
Read MoreSearching for patients to try a new therapy for non-responsive lymphoma after stem-cell transplant.
In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma lose...
Read MoreSearching for patients to try a new therapy for non-responsive lymphoma after stem-cell transplant.
In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma...
Read MoreSearching for patients with previously untreated DLBCL to try this new treatment combination
In a nutshell This study is comparing the effectiveness of R-CHOP chemotherapy with or without enzastaurin (Kinenza) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The main outcome to be measured will be overall survival at the end of the study. The details The current standard first-line treatment for DLBCL is R-CHOP...
Read MoreSearching for patients with relapsed or unresponsive classical HL to try this new treatment option
In a nutshell This Phase 3 trial is evaluating the effectiveness of brentuximab vedotin (Adcetris) with or without nivolumab (Opdivo) for patients with relapsed or unresponsive classical Hodgkin’s lymphoma (cHL). The main outcome to be measured will be survival outcomes at 4 years after treatment. The details Treatment remains...
Read MoreSearching for patients with Hodgkin lymphoma to try a new combination treatment
In a nutshell This study will investigate the effects of a new combination of pembrolizumab (Keytruda) and MK-4280 for the treatment of Hodgkin lymphoma (HL). Side effects and response to treatment will be the main effects measured. The details Pembrolizumab and MK-4280 are both targeted therapies for blood cancers. This means that they specifically...
Read MoreSearching for patients with chronic lymphocytic leukemia to test zanubrutinib compared to ibrutinib
In a nutshell This trial is looking at the effectiveness of zanubrutinib compared to ibrutinib in the treatment of patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). The main outcome to be measured will be overall response rate. The study will be carried out in the United States. The details Chronic...
Read MoreSearching for patients with blood cancer to test new stem cell transplant option
In a nutshell This phase 3 trial is comparing the safety and effectiveness of NiCord stem cell treatment with stem cells taken from the umbilical cord. The main outcome to be measured is the time to neutrophil engraftment (white blood cells accepted by the body that start to grow and make new cells) following transplantation. The details...
Read MoreSearching for patients with relapsed or refractory Hodgkin’s lymphoma to try pembrolizumab plus GVD
In a nutshell This trial is evaluating the effects of second-line pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, doxorubicin) for relapsed (recurrent cancer) or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). The main outcome to be measured is the number of patients who achieve a complete response...
Read MoreSearching for patients with Epstein-Barr positive lymphoma to test a new therapy
In a nutshell This study is investigating the effectiveness of T-cell immunotherapy in Hodgkin’s lymphoma (HL) patients with tumors that are EBV+ (positive for Epstein-Barr virus). This study is recruiting in Duart, California, Washington, D.C., Baltimore, New York, Pittsburgh, and Houston. The details It is thought that individuals who have...
Read MoreSearching for patients with relapsed or refractory follicular lymphoma to test the effectiveness of TGR-1202
In a nutshell This phase 2 clinical trial will test the effectiveness of TGR-1202 in patients with relapsed or refractory follicular lymphoma. The primary outcome will be measured by the overall response rate. This trial is being conducted at the Columbia University Medical Center in New York, New York. The details TGR-1202 (umbralisib)...
Read More